Table 1.
Demographics of Participants With Ovarian Tissue at Risk
| Characteristic | RRSO Group (n = 509) |
Observation/Surveillance Group (n = 283) |
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age at start of follow-up, years | |||||
| Mean | 47.1 | 42.9 | < .001 | ||
| Median | 45.3 | 38.8 | |||
| Range | 31.1–79.0 | 30.0–87.8 | |||
| Mutations | |||||
| BRCA1 | 325 | 64 | 173 | 61 | .49 |
| BRCA2 | 184 | 36 | 110 | 39 | |
| Parous | 419 of 507 | 83 | 203 of 280 | 73 | .001 |
| Prior oral contraceptive use | 342 of 481 | 71 | 178 of 253 | 70 | .86 |
| Prior hormone replacement use | 56 of 488 | 11 | 18 of 267 | 7 | .040 |
| Personal history of breast cancer | 303 | 60 | 133 | 47 | .001 |
| Time to RRSO, months | |||||
| Mean | 10.3 | — | |||
| Median | 4.9 | — | |||
| Range | 0.1–83.3 | — | |||
| Follow-up, months | |||||
| Mean | 40.3 | 37.6 | .15 | ||
| Median | 34.8 | 30.1 | |||
| Range | 6.0–114.6 | 6.2–119.3 | |||
Abbreviation: RRSO, risk-reducing salpingo-oophorectomy.